FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324334423> ?p ?o ?g. }

• W4324334423 endingPage "161" @default.
• W4324334423 startingPage "153" @default.
• W4324334423 abstract "Selecting the appropriate antithrombotic regimen for patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) or have had medically managed acute coronary syndrome (ACS) remains complex. This multi-centre observational study evaluated patterns of antithrombotic therapies utilized among Canadian patients with AF post-PCI or ACS.By retrospective chart audit, 611 non-valvular AF patients [median (interquartile range) age 76 (69-83) years, CHADS2 score 2 (1-3)] who underwent PCI or had medically managed ACS between August 2018 and December 2020 were identified by 68 cardiologists across eight provinces in Canada. Overall, triple antithrombotic therapy [TAT: combined oral anticoagulation (OAC) and dual antiplatelet therapy (DAPT)] was the most common initial antithrombotic strategy, with use in 53.8 % of patients, followed by dual pathway therapy (32.7 % received OAC and a P2Y12 inhibitor, and 4.1 % received OAC and aspirin) and DAPT (9.3 %). Median duration of TAT was 30 (7, 30) days. Compared to the previous CONNECT AF + PCI-I program, there was an increased use of dual pathway therapy relative to TAT over time (P-value <.0001). DOACs (direct oral anticoagulants) represented 90.3 % of all OACs used overall, with apixaban being the most utilized (50.5 %). Proton pump inhibitors were used in 57.0 % of all patients, and 70.1 % of patients on ASA. Planned antithrombotic therapies at 1 year were: 76.2 % OAC monotherapy, 8.3 % OAC + ASA, 7.9 % OAC + P2Y12 inhibitor, 4.3 % DAPT, 1.3 % ASA alone, and <1 % triple therapy.In accordance with recent Canadian Cardiovascular Society guideline recommendations, we observed an increased use of dual pathway therapy relative to TAT over time in both AF patients post-PCI (elective and emergent) and in those with medically managed ACS. Additionally, DOACs have become the prevailing form of anticoagulation across all antithrombotic regimens. Our findings suggest that Canadian physicians are integrating evidence-based approaches to optimally manage the bleeding and thrombotic risks of AF patients post-PCI and/or ACS." @default.
• W4324334423 created "2023-03-16" @default.
• W4324334423 creator A5003117663 @default.
• W4324334423 creator A5005137768 @default.
• W4324334423 creator A5009428097 @default.
• W4324334423 creator A5009608699 @default.
• W4324334423 creator A5012104509 @default.
• W4324334423 creator A5014953334 @default.
• W4324334423 creator A5016160940 @default.
• W4324334423 creator A5017666786 @default.
• W4324334423 creator A5019425754 @default.
• W4324334423 creator A5020027002 @default.
• W4324334423 creator A5024193392 @default.
• W4324334423 creator A5026161853 @default.
• W4324334423 creator A5027134936 @default.
• W4324334423 creator A5028527452 @default.
• W4324334423 creator A5033074276 @default.
• W4324334423 creator A5033224816 @default.
• W4324334423 creator A5035288402 @default.
• W4324334423 creator A5037522111 @default.
• W4324334423 creator A5038392664 @default.
• W4324334423 creator A5039692883 @default.
• W4324334423 creator A5039972459 @default.
• W4324334423 creator A5040549843 @default.
• W4324334423 creator A5040812704 @default.
• W4324334423 creator A5046111545 @default.
• W4324334423 creator A5047187243 @default.
• W4324334423 creator A5053749161 @default.
• W4324334423 creator A5055631125 @default.
• W4324334423 creator A5056476744 @default.
• W4324334423 creator A5056667853 @default.
• W4324334423 creator A5056732331 @default.
• W4324334423 creator A5061148228 @default.
• W4324334423 creator A5064778694 @default.
• W4324334423 creator A5065177021 @default.
• W4324334423 creator A5065664971 @default.
• W4324334423 creator A5067460303 @default.
• W4324334423 creator A5069809974 @default.
• W4324334423 creator A5072116483 @default.
• W4324334423 creator A5072521028 @default.
• W4324334423 creator A5074865855 @default.
• W4324334423 creator A5079600734 @default.
• W4324334423 creator A5081205474 @default.
• W4324334423 creator A5082319577 @default.
• W4324334423 creator A5083162965 @default.
• W4324334423 creator A5084936680 @default.
• W4324334423 date "2023-08-01" @default.
• W4324334423 modified "2023-10-18" @default.
• W4324334423 title "Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program" @default.
• W4324334423 cites W1596667386 @default.
• W4324334423 cites W1981131402 @default.
• W4324334423 cites W2015249021 @default.
• W4324334423 cites W2022506351 @default.
• W4324334423 cites W2062449174 @default.
• W4324334423 cites W2080820967 @default.
• W4324334423 cites W2096606175 @default.
• W4324334423 cites W2097854437 @default.
• W4324334423 cites W2159370853 @default.
• W4324334423 cites W2494452675 @default.
• W4324334423 cites W2556417520 @default.
• W4324334423 cites W2615490950 @default.
• W4324334423 cites W2749929702 @default.
• W4324334423 cites W2776894078 @default.
• W4324334423 cites W2887586296 @default.
• W4324334423 cites W2921724943 @default.
• W4324334423 cites W2970790333 @default.
• W4324334423 cites W2972299172 @default.
• W4324334423 cites W2989810556 @default.
• W4324334423 cites W3013012074 @default.
• W4324334423 cites W3082188176 @default.
• W4324334423 cites W3089760978 @default.
• W4324334423 cites W3094096718 @default.
• W4324334423 cites W3177879296 @default.
• W4324334423 cites W3210287281 @default.
• W4324334423 doi "https://doi.org/10.1016/j.jjcc.2023.03.004" @default.
• W4324334423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36931433" @default.
• W4324334423 hasPublicationYear "2023" @default.
• W4324334423 type Work @default.
• W4324334423 citedByCount "0" @default.
• W4324334423 crossrefType "journal-article" @default.
• W4324334423 hasAuthorship W4324334423A5003117663 @default.
• W4324334423 hasAuthorship W4324334423A5005137768 @default.
• W4324334423 hasAuthorship W4324334423A5009428097 @default.
• W4324334423 hasAuthorship W4324334423A5009608699 @default.
• W4324334423 hasAuthorship W4324334423A5012104509 @default.
• W4324334423 hasAuthorship W4324334423A5014953334 @default.
• W4324334423 hasAuthorship W4324334423A5016160940 @default.
• W4324334423 hasAuthorship W4324334423A5017666786 @default.
• W4324334423 hasAuthorship W4324334423A5019425754 @default.
• W4324334423 hasAuthorship W4324334423A5020027002 @default.
• W4324334423 hasAuthorship W4324334423A5024193392 @default.
• W4324334423 hasAuthorship W4324334423A5026161853 @default.
• W4324334423 hasAuthorship W4324334423A5027134936 @default.
• W4324334423 hasAuthorship W4324334423A5028527452 @default.
• W4324334423 hasAuthorship W4324334423A5033074276 @default.
• W4324334423 hasAuthorship W4324334423A5033224816 @default.
• W4324334423 hasAuthorship W4324334423A5035288402 @default.
• W4324334423 hasAuthorship W4324334423A5037522111 @default.

• next